Statement of Changes in Beneficial Ownership (4)
04 Noviembre 2019 - 3:16PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Curran Terrie |
2. Issuer Name and Ticker or Trading Symbol
CELGENE CORP /DE/
[
CELG
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) SEE REMARKS
|
(Last)
(First)
(Middle)
C/O CELGENE CORPORATION, 86 MORRIS AVENUE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/31/2019
|
(Street)
SUMMIT, NJ 07901
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
10/31/2019
|
|
M
|
|
3281
|
A
|
$0 (1)(2)
|
5436
|
D
|
|
Common Stock
|
10/31/2019
|
|
F
|
|
1123
|
D
|
$108.03
|
4313
|
D
|
|
Common Stock
|
|
|
|
|
|
|
|
926
|
I
|
401(k) Plan
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code (Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)
|
8. Price of Derivative Security (Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Restricted Stock Unit
|
(1)(2)
|
10/31/2019
|
|
M
|
|
|
3281
|
(1)
|
(1)
|
Common Stock
|
3281
|
$0 (3)
|
0
|
D
|
|
Explanation of Responses:
|
(1)
|
The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock.
|
(2)
|
Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
|
(3)
|
The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan).
|
Remarks: PRESIDENT, GLOBAL INFLAMMATION AND IMMUNOLOGY |
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Curran Terrie C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT, NJ 07901
|
|
|
SEE REMARKS
|
|
Signatures
|
/s/ Jonathan Biller, Attorney-in-Fact
|
|
11/4/2019
|
**Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person, see Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Celgene (NASDAQ:CELG)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Celgene (NASDAQ:CELG)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
Real-Time news about Celgene Corporation (NASDAQ): 0 recent articles
Más de Celgene Corp /de/ Artículos de Noticias
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.